Seeking Alpha

Halozyme Therapeutics (HALO +4.4%) moves up after saying results from a Phase 2 study of...

Halozyme Therapeutics (HALO +4.4%) moves up after saying results from a Phase 2 study of rHuPH20, a prandial insulin, met its primary endpoint for blood sugar measurement in patients with Type 1 diabetes. Additionally, data from the study further indicated that rHuPH20 also reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs